Endocrine Abstracts

Almost all tumours display increased activity of components of the phosphoinositide 3-kinase (PI3K) signalling pathway. In particular, activating mutations in the PI3K catalytic subunit, p110alpha, and loss of function mutations of the opposing PTEN phosphatase are amongst the most frequent alterations in human cancers. Our current work aims to understand how loss of PTEN function contributes to tumour development through two related projects. Firstly, we are attempting to add...